PCSA Research and Charts

PCSA - Processa Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-01-06)

Last 0.96	Change ⇓ -0.04 (-4.10%)	Volume 85,446
	Open 1.01	High 1.08	Low 0.93

8EMA (Daily) 0.94	40EMA (Daily) 1.04	50EMA (Daily) 1.07	STO (Daily) 28.451	MACD Hist (Daily) 0.012
8EMA (Weekly) 1.005	40EMA (Weekly) 1.30	50EMA (Weekly) 1.33	STO (Weekly) 21.057	MACD Hist (Weekly) -0.024


Company Profile
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on the development of drug products that are intended to improve the survival and quality of life for patients who have an unmet medical need. The company's lead product, PCS499 is an oral tablet that is an analog of an active metabolite of an already approved drug. It focuses on fibrotic related diseases such as focal segmental glomerulosclerosis, idiopathic pulmonary fibrosis. Its pipeline products comprise PCS6422, PCS12852, and PCS100.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.